Claims

1. The use of MAP in the manufacture of a composition for the treatment or prevention of melanin pigmentation.

2. The use according to claim 1, wherein the MAP comprises one or more of the sub-types selected from the group: the mefp-1 subtypes mefp-1, mefp-2, mefp-3, mefp-4, mefp-5, mefp-6, the collagens pre-COL-P, pre-COL-D, pre-COL-NG, and the mussel feet matrix proteins PTMP and DTMP.

3. The use according to claim 2, wherein the MAP comprises one or more of the sub-types selected from the group mefp-1, mefp-2, mefp-3, mefp-4, mefp-5 and mefp-6.

4. The use according to claim 3, wherein the MAP comprises mefp-1.

5. The use according to any one of claims 1-4, wherein the MAP concentration is 0.1-15.0 mg/mL.

6. The use according to any one of claims 1-5, wherein the MAP is a liquid formulation, a gel formulation, a lotion, a paste, a therapy patch, or a foam formulation.

7. The use according to any one of claims 1-6, wherein MAP in the final product is in a range of pH 1.0-7.0, and in particular, in a range of pH 3.0-6.5.

8. The use according to any one of claims 1-7, wherein the melanin pigmentation is selected from the group: chloasma, freckles, melanosis, chromatosis and skin cancers.

9. The use according to any one of claims 1-8, wherein the melanin pigmentation comprises melanoma or chromatosis caused by exposure to the sun or a skin disease.

10. The use according to any one of claims 1-9, wherein the MAP is combined with an enzyme in use.

11. The use according to claim 10, wherein the MAP is used directly or after a micro-wound surface is created first.

12. The use according to claim 11, wherein the method to create a micro-wound surface is a micro-needle, a rolling needle or a laser.

13. The use according to any one of claims 7-12, wherein the enzyme is selected from: trypsin; a collagenase; a caseinase; chymotrypsin; a carboxypeptidase; a ceratinase; a enterokinase or rennet.

14. The use according to claim 13, wherein the enzyme is trypsin.

15. The use according to any one of claims 7-14, wherein the manner of use of the combination of MAP and an enzyme comprises:

(a) spraying the enzyme first to decompose the corneous layer on the skin surface, spraying the enzyme again, and then spraying MAP;

(b) spraying MAP first, and then spraying the enzyme; mixing MAP with the enzyme and then spraying it for use; or

(c) spraying the enzyme first, and then spraying MAP.

16. The use according to claim 15, wherein the MAP and the enzyme are provided in different packages.

17. The use according to any one of claims 7-16 wherein the MAP is provided in the form of a mixture of hydrolyzed MAP peptides; or the form of a single hydrolyzed MAP peptide.

18. The use according to any one of claims 7-17, wherein the molar ratio of MAP to the enzyme is in the range of 0.1:1-100:1.

19. The use according to claim 18, wherein the molar ratio is in the range of 1:1-50:1.

20. The use according to any one of claims 1-19, wherein the composition is suitable for external skin application.

21. The use according to any one of claims 1-20 wherein the composition is a medicine, a cosmetic preparation, a disinfecting product, a healthcare product, a food or a household chemical.

22. A hydrolyzed MAP peptide.